127 related articles for article (PubMed ID: 21684157)
1. Novel nanomolar imidazo[4,5-b]pyridines as selective nitric oxide synthase (iNOS) inhibitors: SAR and structural insights.
Grädler U; Fuchss T; Ulrich WR; Boer R; Strub A; Hesslinger C; Anézo C; Diederichs K; Zaliani A
Bioorg Med Chem Lett; 2011 Jul; 21(14):4228-32. PubMed ID: 21684157
[TBL] [Abstract][Full Text] [Related]
2. The discovery of novel, potent and highly selective inhibitors of inducible nitric oxide synthase (iNOS).
Cheshire DR; Åberg A; Andersson GM; Andrews G; Beaton HG; Birkinshaw TN; Boughton-Smith N; Connolly S; Cook TR; Cooper A; Cooper SL; Cox D; Dixon J; Gensmantel N; Hamley PJ; Harrison R; Hartopp P; Käck H; Leeson PD; Luker T; Mete A; Millichip I; Nicholls DJ; Pimm AD; St-Gallay SA; Wallace AV
Bioorg Med Chem Lett; 2011 Apr; 21(8):2468-71. PubMed ID: 21398123
[TBL] [Abstract][Full Text] [Related]
3. The novel imidazopyridine 2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) is a highly selective inhibitor of the inducible nitric-oxide synthase.
Strub A; Ulrich WR; Hesslinger C; Eltze M; Fuchss T; Strassner J; Strand S; Lehner MD; Boer R
Mol Pharmacol; 2006 Jan; 69(1):328-37. PubMed ID: 16223957
[TBL] [Abstract][Full Text] [Related]
4. BYK191023 (2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3h-imidazo[4,5-b]pyridine) is an NADPH- and time-dependent irreversible inhibitor of inducible nitric-oxide synthase.
Tiso M; Strub A; Hesslinger C; Kenney CT; Boer R; Stuehr DJ
Mol Pharmacol; 2008 Apr; 73(4):1244-53. PubMed ID: 18178668
[TBL] [Abstract][Full Text] [Related]
5. IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding.
Buckley GM; Ceska TA; Fraser JL; Gowers L; Groom CR; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V
Bioorg Med Chem Lett; 2008 Jun; 18(11):3291-5. PubMed ID: 18482836
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a series of aminopiperidines as novel iNOS inhibitors.
Le Bourdonnec B; Leister LK; Ajello CA; Cassel JA; Seida PR; O'Hare H; Gu M; Chu GH; Tuthill PA; DeHaven RN; Dolle RE
Bioorg Med Chem Lett; 2008 Jan; 18(1):336-43. PubMed ID: 18024030
[TBL] [Abstract][Full Text] [Related]
7. Structural analysis of isoform-specific inhibitors targeting the tetrahydrobiopterin binding site of human nitric oxide synthases.
Matter H; Kumar HS; Fedorov R; Frey A; Kotsonis P; Hartmann E; Fröhlich LG; Reif A; Pfleiderer W; Scheurer P; Ghosh DK; Schlichting I; Schmidt HH
J Med Chem; 2005 Jul; 48(15):4783-92. PubMed ID: 16033258
[TBL] [Abstract][Full Text] [Related]
8. Phenylpyrrole derivatives as neural and inducible nitric oxide synthase (nNOS and iNOS) inhibitors.
López Cara LC; Camacho ME; Carrión MD; Tapias V; Gallo MA; Escames G; Acuña-Castroviejo D; Espinosa A; Entrena A
Eur J Med Chem; 2009 Jun; 44(6):2655-66. PubMed ID: 19117642
[TBL] [Abstract][Full Text] [Related]
9. Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models.
Bonnefous C; Payne JE; Roppe J; Zhuang H; Chen X; Symons KT; Nguyen PM; Sablad M; Rozenkrants N; Zhang Y; Wang L; Severance D; Walsh JP; Yazdani N; Shiau AK; Noble SA; Rix P; Rao TS; Hassig CA; Smith ND
J Med Chem; 2009 May; 52(9):3047-62. PubMed ID: 19374401
[TBL] [Abstract][Full Text] [Related]
10. The rational design of inhibitors of nitric oxide formation by inducible nitric oxide synthase.
Whitlow M; Adler M; Davey D; Huang Q; Koovakkat S; Parkinson JF; Pham E; Polokoff M; Xu W; Yuan S; Phillips G
Bioorg Med Chem Lett; 2007 May; 17(9):2505-8. PubMed ID: 17336523
[TBL] [Abstract][Full Text] [Related]
11. In vivo characterization of the novel imidazopyridine BYK191023 [2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine], a potent and highly selective inhibitor of inducible nitric-oxide synthase.
Lehner MD; Marx D; Boer R; Strub A; Hesslinger C; Eltze M; Ulrich WR; Schwoebel F; Schermuly RT; Barsig J
J Pharmacol Exp Ther; 2006 Apr; 317(1):181-7. PubMed ID: 16368897
[TBL] [Abstract][Full Text] [Related]
12. Heteroaromatic-aminomethyl quinolones: potent and selective iNOS inhibitors.
Durón SG; Lindstrom A; Bonnefous C; Zhang H; Chen X; Symons KT; Sablad M; Rozenkrants N; Zhang Y; Wang L; Yazdani N; Shiau AK; Noble SA; Rix P; Rao TS; Hassig CA; Smith ND
Bioorg Med Chem Lett; 2012 Jan; 22(2):1237-41. PubMed ID: 22182498
[TBL] [Abstract][Full Text] [Related]
13. Identification and SAR of selective inducible nitric oxide synthase (iNOS) dimerization inhibitors.
Gahman TC; Herbert MR; Lang H; Thayer A; Symons KT; Nguyen PM; Massari ME; Dozier S; Zhang Y; Sablad M; Rao TS; Noble SA; Shiau AK; Hassig CA
Bioorg Med Chem Lett; 2011 Nov; 21(22):6888-94. PubMed ID: 21986586
[TBL] [Abstract][Full Text] [Related]
14. L-arginine binding to human inducible nitric oxide synthase: an antisymmetric funnel route toward isoform-specific inhibitors?
Floquet N; Hernandez JF; Boucher JL; Martinez J
J Chem Inf Model; 2011 Jun; 51(6):1325-35. PubMed ID: 21574590
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of iNOS by benzyl- and dibenzyl derivatives of N-(3-aminobenzyl)acetamidine.
Fantacuzzi M; Maccallini C; Lannutti F; Patruno A; Masella S; Pesce M; Speranza L; Ammazzalorso A; De Filippis B; Giampietro L; Re N; Amoroso R
ChemMedChem; 2011 Jul; 6(7):1203-6. PubMed ID: 21567968
[No Abstract] [Full Text] [Related]
16. Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors.
Davey DD; Adler M; Arnaiz D; Eagen K; Erickson S; Guilford W; Kenrick M; Morrissey MM; Ohlmeyer M; Pan G; Paradkar VM; Parkinson J; Polokoff M; Saionz K; Santos C; Subramanyam B; Vergona R; Wei RG; Whitlow M; Ye B; Zhao ZS; Devlin JJ; Phillips G
J Med Chem; 2007 Mar; 50(6):1146-57. PubMed ID: 17315988
[TBL] [Abstract][Full Text] [Related]
17. Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models.
Payne JE; Bonnefous C; Symons KT; Nguyen PM; Sablad M; Rozenkrants N; Zhang Y; Wang L; Yazdani N; Shiau AK; Noble SA; Rix P; Rao TS; Hassig CA; Smith ND
J Med Chem; 2010 Nov; 53(21):7739-55. PubMed ID: 20931971
[TBL] [Abstract][Full Text] [Related]
18. Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase.
Hah JM; Martásek P; Roman LJ; Silverman RB
J Med Chem; 2003 Apr; 46(9):1661-9. PubMed ID: 12699384
[TBL] [Abstract][Full Text] [Related]
19. Pyrazoles and pyrazolines as neural and inducible nitric oxide synthase (nNOS and iNOS) potential inhibitors (III).
Carrión MD; López Cara LC; Camacho ME; Tapias V; Escames G; Acuña-Castroviejo D; Espinosa A; Gallo MA; Entrena A
Eur J Med Chem; 2008 Nov; 43(11):2579-91. PubMed ID: 18325637
[TBL] [Abstract][Full Text] [Related]
20. Functionalized 3-amino-imidazo[1,2-a]pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors.
Odell LR; Nilsson MT; Gising J; Lagerlund O; Muthas D; Nordqvist A; Karlén A; Larhed M
Bioorg Med Chem Lett; 2009 Aug; 19(16):4790-3. PubMed ID: 19560924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
